Mon.Aug 08, 2022

article thumbnail

What’s the most significant change in DTC?

World of DTC Marketing

Consumers have changed their shopping behavior due to the pandemic, and some of those changes are relevant for pharma marketers. The days of someone seeing an ad for a prescription drug and rushing to ask their doctor about it have replaced the quest for more information, usually online. CPG brands have finally admitted that consumers are changing how they purchase products and brands.

article thumbnail

Digital health app linked to better outcomes in heart failure

pharmaphorum

A study of a mobile health app used to support patients hospitalised with heart failure has concluded that it provided a modest improvement in quality-of-life scores, as well as better clinical outcomes. The finding comes from the large-scale CONNECT-HF cluster study, which looked at various patient engagement and education interventions to see if they could help patients with heart failure do better after discharge from hospital.

Medical 144
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Analysis: What CVS Health’s interest in primary and home care means

MedCity News

An expert industry observer said CVS Health’s move into primary care is both offensive and defensive, but perhaps more importantly a natural evolution of a company with such a large healthcare footprint.

article thumbnail

AstraZeneca-Daiichi Sankyo’s Enhertu gets US FDA approval for breast cancer

Pharmaceutical Technology

AstraZeneca and Daiichi Sankyo ’s Enhertu (trastuzumab deruxtecan) has received expanded approval from the US Food and Drug Administration (FDA) to treat adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer. The treatment is indicated for patients who have previously received chemotherapy in the metastatic setting or recurred during or within six months of receiving adjuvant chemotherapy.

article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

Health insurance providers assisted growth in behavioral health access, AHIP survey shows

MedCity News

The number of in-network behavioral health providers increased by 48% in the last three years among commercial health plans. The number of in-network inpatient psychiatric hospitals rose by 40%.

Insurance 109
article thumbnail

Pfizer vaults into sickle cell market as GBT deal confirmed

pharmaphorum

Pfizer’s reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics (GBT) has been confirmed, with the $68.50-per-share deal valuing GBT at $5.4 billion. As we reported this morning, the deal gives Pfizer already-approved SCD therapy Oxbryta (voxelator) – which industry watchers reckon could see a dramatic uptick in sales with Pfizer’s marketing muscle – plus a phase 3 antibody candidate, a phase 1 follow-up to Oxbryta that could offer improved dosing.

Marketing 108

More Trending

article thumbnail

US FDA grants approval for Orion-Bayer’s Nubeqa combo for prostate cancer

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted approval for a supplemental New Drug Application (sNDA) of Orion and its partner Bayer ’s Nubeqa (darolutamide) plus docetaxel to treat metastatic hormone-sensitive prostate cancer (mHSPC) patients. The latest approval is based on positive data from the multicentre, double-blind, randomised, placebo-controlled Phase III ARASENS clinical trial that analysed the safety and efficacy of oral darolutamide plus androgen deprivation therapy (ADT) an

article thumbnail

How payers are using predictive analytics and virtual care to improve care delivery [Sponsored]

MedCity News

As part of its Envision U.S. Healthcare Summit, Microsoft conducted interviews with executives at Aetna CVS Health and Humana to highlight some of the ways these companies are adapting to consumerization of healthcare.

article thumbnail

Upcycling CDs as Flexible Biosensors

Medgadget

A team of scientists at Binghamton University in New York State have developed a technique that lets them salvage material from old CDs to make flexible biosensors that are inexpensive and relatively simple to produce. The method involves using a chemical process and sticky tape to peel off the metal coating from the disks, and then using a crafting cutter to shape the flexible material as required.

article thumbnail

GSK pays $100M to partner on a cancer drug with new twist on immunotherapy

MedCity News

GSK is partnering with Mersana Therapeutics on the development of an antibody-drug conjugate that is approaching Phase 1 testing. Unlike other ADCs that deliver a toxic drug payload, the Mersana drug is designed to activate the innate immune system to fight tumor cells.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Lilly to pay more than $180mn for defrauding US Medicaid Program

European Pharmaceutical Review

Eight years after the whistle was blown on Eli Lilly for allegedly underpaying the rebates required of drug manufacturers under the US Medicaid Drug Rebate Program, a jury has ordered the company to pay more than $61 million in damages. However, as the whistleblower Ronald J Streck filed a False Claims Act lawsuit, the damages will be trebled and the final judgment will be over $183 million, according to Streck’s legal team.

article thumbnail

Unlocking interoperability for digital transformation with a blockchain-powered network

MedCity News

Payers, providers, financial institutions and tech innovators – often known as “frenemies” – need to set aside their old competitive spirit and come together as one team for the healthcare industry to be truly interoperable.

article thumbnail

DeepIntent Names Amit Chaturvedi as Chief Operating Officer

PharmExec

Seasoned executive brings expertise with high-growth companies as pharma programmatic advertising spending dramatically increases.

Pharma 98
article thumbnail

Pfizer to buy sickle cell disease biotech Global Blood Therapeutics in $5.4B deal

MedCity News

Pfizer’s own R&D efforts in sickle cell disease have fallen short, so the pharmaceutical giant is turning to M&A to gain a presence in the blood disorder. The acquisition of Global Blood therapeutics brings the commercialized drug Oxbryta plus a pipeline of other therapeutic candidates.

article thumbnail

Accelerating Clinical Supply Through Integrated Drug Development

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

article thumbnail

Top 10 Leadership Qualities of a Good Medical Sales Team Leader

MedReps

Medical sales team leaders have a tough job on their hands. Not only is the job constantly in flux and always changing, but you need to keep up with your team, learn new skills and more in order to remain a motivated, functional leader. This complex job is made easier when you have all of the necessary leadership qualities. The Most Important Leadership Qualities.

article thumbnail

Register for MedCity INVEST Digital Health and take part in a discussion on pharmacy benefit management

MedCity News

The MedCity INVEST Digital Health conference in Dallas September 28 in collaboration with Health Wildcatters marks our first conference in the Lone Star state and new themes embracing employee benefits and the financial experience in healthcare. Register today!

article thumbnail

US FDA approves Pfizer-Myovant’s Myfembree for endometriosis pain

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted approval for Pfizer and Myovant Sciences ’ Myfembree (relugolix 40mg, estradiol 1mg and norethindrone acetate 0.5mg) to manage moderate-to-severe pain linked with endometriosis in pre-menopausal women. Myfembree is a one-pill treatment indicated to be administered once daily for a treatment period of up to 24 months.

article thumbnail

Sibel Health scores $33M to scale wearable-based RPM platform

MedCity News

Medical technology startup Sibel Health recently closed a $33 million Series B funding round. It will use the funds to grow the company and scale commercialization of its Anne One platform, which captures users’ vital signs using wearable sensors.

Medical 94
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Bayer bags swift OK for Nubeqa in metastatic prostate cancer

pharmaphorum

Bayer has won a key FDA approval to extend the use of its prostate cancer therapy Nubeqa, as it tries to claim market share from rival drugs and fulfil its aim of building the drug into a €3 billion ($3.1 billion) blockbuster. The US regulator has approved Nubeqa (darolutamide) in combination with docetaxel chemotherapy for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), adding to its earlier indication in non-metastatic castration-resistant prostate cancer (nmCRPC).

Sales 57
article thumbnail

EQRx announces further results from phase 3 trial of sugemalimab

PharmaTimes

Study involved patients with locally advanced, unresectable stage 3 non-small cell lung cancer

article thumbnail

Study: Green Tea Extract Reduces Blood Sugar Levels, Improves Gut Health

Pharmacy Times

Investigators found that the health risks linked to the condition known as metabolic syndrome could be diminished by green tea’s anti-inflammatory benefits in the gut.

69
article thumbnail

Building a Patient-First Medication Access Journey

Pharmaceutical Commerce

Medication access solutions should be curated to the specific needs of the medication and patients themselves. Read more about medication access, affordability and adherence capabilities in the CoverMyMeds Solutions Overview.

Medical 52
article thumbnail

The New Clinical Trial Supply Chain: Resilient, Flexible, and Patient-Centric

The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.

article thumbnail

Karuna Therapeutics scores phase 3 win for schizophrenia therapy KarXT

pharmaphorum

Karuna Therapeutics has unveiled positive topline results from its phase 3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT (xanomeline-trospium), in adults with schizophrenia. KarXT is an oral, investigational muscarinic agonist comprised of the muscarinic agonist xanomeline and muscarinic antagonist trospium, developed for treating psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.

article thumbnail

How to Plan Out Your Sales Training Program Schedule

Quantified

Any organization committed to staying competitive and winning business must invest in sales team training. Today’s sales reps must be experts in what they do to impress customers who are more informed than ever. Buyers no longer settle for basic product details and standard sales pitches. They want partners in the sales process— people who understand their needs.

article thumbnail

Future of work hiring levels in the pharmaceutical industry rose in July 2022

Pharmaceutical Technology

The proportion of pharmaceutical companies hiring for future of work related positions rose in July 2022 compared with the equivalent month last year, with 48.5% of the companies included in our analysis recruiting for at least one such position. This latest figure was higher than the 42.9% of companies who were hiring for future of work related jobs a year ago and an increase compared to the figure of 46.6% in June 2022.

article thumbnail

How to Optimize the Digital Patient Experience

LEVO Health

In the last decade, technology has revolutionized the field of healthcare. With the ongoing pandemic only escalating our reliance on technology, patients now turn towards digital channels more than ever before for their healthcare needs. As a result, medical practices must provide a seamless, convenient, and personalized digital patient experience to maintain patient satisfaction and retention.

article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

AZ gets FDA nod for Enhertu in first HER2-low cancer

pharmaphorum

The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu as the first targeted therapy for HER2-low breast cancer, a new category of the disease that was once lumped under the HER2-negative classification. It has the potential to be a sizeable new indication for Enhertu (trastuzumab deruxtecan), a HER2-targeting antibody-drug conjugate, and central to AZ and Daiichi Sankyo’s hopes of unlocking multibillion-dollar sales for the drug.

FDA 52
article thumbnail

Sage Growth Partners Expands Commercial Leadership

PharmExec

National healthcare consultancy and marketing firm hires Senior Vice President of Business Development to meet growing market demand and client partnership opportunities.

article thumbnail

Pfizer bid for sickle cell drug developer GBT said to be imminent

pharmaphorum

Pfizer is on the brink of announcing a deal to buy Global Blood Therapeutics (GBT) and its oral therapy Oxbryta for sickle cell disease for around $5 billion, according to press reports. A deal could be announced as early as today, when GBT is scheduled to report its second quarter results, according to a Wall Street Journal report citing people familiar with the matter.

FDA 52
article thumbnail

Hormone Therapy for Prostate Cancer May Increase Risk of Mortality From Cardiovascular Disease

Pharmacy Times

Use of hormone therapy to treat prostate cancer may require more consideration by health care providers as new study shows the therapy may increase the risk of heart disease.

62
article thumbnail

Clinical Supply Strategies for CROs

When a CRO is bidding on a project where clinical supplies will be one of the aspects to manage on behalf of the client via a partner, leveraging the expertise of a chosen clinical supply partner can be a valuable resource in demonstrating the CRO’s understanding of and ability to deliver upon critical drug-supply related aspects of the project, and ability to hit key milestones such as FPI for their client.